Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre‐specified patient subgroups in the Effisayil 1 study

Autor: A. D. Burden, Y. Okubo, M. Zheng, D. Thaçi, P. van de Kerkhof, N. Hu, M. Quaresma, C. Thoma, S. E. Choon

Publikováno v: Experimental Dermatology.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a4611262762663da538974c158c063e2
https://doi.org/10.1111/exd.14824

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study

Autor: Richard B. Warren, Kathleen McElhone, K.J. Mason, Darren M. Ashcroft, Watcharee Rungapiromnan, Mark Lunt, A D Burden, Christopher E.M. Griffiths, Michael Rutter

Publikováno v: Rungapiromnan, W, Mason, K J, Lunt, M, Mcelhone, K, Burden, A D, Rutter, M K, Warren, R B, Griffiths, C E M & Ashcroft, D M 2020, ' Risk of Major Cardiovascular Events in Patients with Psoriasis Receiving Biologic Therapies: a Prospective Cohort Study ', Journal of the European Academy of Dermatology and Venereology, vol. 34, pp. 769-778 . https://doi.org/10.1111/jdv.16018

BACKGROUND The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. OBJECTIVES To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af0e9559ba4210453621b8d166de09e6
https://doi.org/10.1111/jdv.16018

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: An Updated Systematic Review and Meta-Analysis

Autor: A D Burden, Martinsixtus C. Ezejimofor, R Parslew, Z.Z.N. Yiu, R T Woolf, L S Exton, Satveer K. Mahil, Ruth Murphy, Catherine H. Smith, M F Mohd Mustapa, C. M. Owen, L Manounah

BackgroundThe increase in the number of available biologic agents for psoriasis has led to an urgent need to evaluate their associated risk of serious infections to help inform clinical decisions.MethodologyWe systematically searched PubMed, Medline,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9e828e611e1f87ce3ce8294db8acdce8
https://doi.org/10.1101/2021.08.27.21262722

Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non-biologic systemic therapies

Autor: Josh Richards, Marilyn Benham, Ian Evans, M.M. Soliman, Anthony Ormerod, Adèle C. Green, Tess McPherson, Nick J. Reynolds, C. M. Owen, Eleanor Pearson, Sagair Hussain, Philip Laws, Jonathan Barker, Christopher E.M. Griffiths, Linda Lawson, Teena Mackenzie, Catherine H. Smith, K.J. Mason, A D Burden, C.E. Kleyn, Ruth Murphy, Fiona Browne, Haibat Ali, Kathleen McElhone, Brian Kirby, Richard B. Warren, Mark Lunt

Publikováno v: Journal of the European Academy of Dermatology and Venereology : JEADVReferences. 35(8)

There are concerns that immunomodulatory therapies may increase the risks of developing basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC) in patients with moderate-severe psoriasis. A systematic review showed that psoriasis patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17bf74ba2512bd29d4d224a1d631c781
https://pubmed.ncbi.nlm.nih.gov/33866626

Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis

Autor: Catherine H. Smith, R Parslew, M F Mohd Mustapa, A D Burden, Zenas Z N Yiu, C. M. Owen, Martinsixtus C. Ezejimofor, Laura C Coates, L Manounah, Satveer K. Mahil, Ruth Murphy, L S Exton, A McGuire, M de Brito, Olalekan A. Uthman, R T Woolf

Publikováno v: Mahil, S K, Ezejimofor, M C, Exton, L S, Manounah, L, Burden, A D, Coates, L C, de Brito, M, McGuire, A, Murphy, R, Owen, C M, Parslew, R, Woolf, R T, Yiu, Z Z N, Uthman, O A, Mohd Mustapa, M F & Smith, C H 2020, ' Comparing the efficacy and tolerability of biologic therapies in psoriasis : an updated network meta-analysis ', The British journal of dermatology . https://doi.org/10.1111/bjd.19325

Background The rapid expansion of psoriasis biologics has led to an urgent need to understand their relative efficacy and tolerability to inform treatment decisions better and, specifically, to inform guideline development. Objectives To update a 201

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a99b76898f3cc0e99f3510c79065a917
https://pubmed.ncbi.nlm.nih.gov/32562551